Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00258739
Status:
COMPLETED
Last Update Posted:
2009-12-07
First Post:
2005-11-23
Brief Title:
Docetaxel in Non Small Cell Lung Cancer NSCLC
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Phase II Randomized Study With Docetaxel-gemcitabine Followed by Radiotherapy vs Concomitant Treatment Radiotherapy and Carboplatine-docetaxel Followed by Docetaxel-gemcitabine Versus Docetaxel-gemcitabine Followed by Concomitant Treatment Radiotherapy and Carboplatine-docetaxel in Stage III NSCLC
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary objective
To classify the 2 study groups according to the tumoral response
Secondary objectives
To evaluate the percentage of focused control per year
To calculate the time until progression
To evaluate the safety profile
To classify the 2 study groups according to the tumoral response
Secondary objectives
To evaluate the percentage of focused control per year
To calculate the time until progression
To evaluate the safety profile
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None